Ireland’s ambitions for medical research took another notable step forward this week as gov.ie confirmed a key leadership appointment in the country’s evolving clinical research framework. In a move likely to matter to patients, researchers, hospitals and industry alike, the Department of Health has announced that Professor Donal Brennan will chair the new Clinical Trials Advisory Council, placing Clinical Trials Ireland firmly at the centre of national health innovation.
Professor Brennan is a Professor of Gynaecological Oncology at University College Dublin and a Consultant Gynaecological Oncologist at the Mater Misericordiae University Hospital. He previously led the National Clinical Trials Oversight Group, where he helped shape the final reform blueprint for Ireland’s clinical trials system. That earlier work now feeds directly into the mission of the new council.
Clinical Trials Ireland gets new leadership under CTAC
The appointment is a major milestone for Clinical Trials Ireland because the new Clinical Trials Advisory Council, or CTAC, is designed to turn strategy into action. The council will guide implementation of recommendations aimed at making Ireland a stronger destination for high-quality clinical research and a better place for patients to access emerging therapies.
According to the Department of Health, the council will draw members from across the health research ecosystem, including:
- patient representatives
- academic experts
- healthcare providers
- regulators and public bodies
- industry and government stakeholders
This broad membership model is important because modern clinical trials rely on cooperation between the Health Service Executive (HSE), universities, hospitals, regulators such as the HPRA and wider state systems linked to Health, Enterprise, Trade and Employment, and Finance.
Read more: latest Ireland government health policy updates and public sector leadership news
Why the Clinical Trials Ireland agenda matters
The wider goal behind Clinical Trials Ireland is not just administrative reform. Clinical trials help bring new medicines, technologies and treatment pathways to patients while improving standards of care across the health system. A stronger national framework could also enhance Ireland’s attractiveness for international investment, supporting the life sciences sector alongside agencies and institutions such as IDA Ireland, Enterprise Ireland and the Higher Education Authority (HEA).
Minister for Health Jennifer Carroll MacNeill said the new council represents an important step in building Ireland’s standing in the global clinical trials landscape. The government sees this work as aligned with Ireland’s role in European discussions around the EU Biotech Act and with the development of a National Life Sciences Strategy.
That means Clinical Trials Ireland now sits at the intersection of several national priorities:
- better patient access to innovative treatments
- stronger research capacity in hospitals and universities
- greater competitiveness in life sciences and biotechnology
- improved coordination across public policy and regulation
What happens next
The full membership of CTAC is expected to be completed in the coming weeks following an expression of interest process run by the Department of Health. Once established, the council is expected to focus on delivering measurable reform based on the earlier blueprint produced by the National Clinical Trials Oversight Group.
Its success will likely depend on collaboration across the public sector, from core departments on Health and Public Expenditure to data, research and oversight bodies including the Data Protection Commission (DPC), CSO and relevant healthcare regulators.
Explore more: top Ireland healthcare innovation news, biotech investment stories and medical research developments
FAQs on Clinical Trials Ireland and the new council
Who has been appointed chair of CTAC?
Professor Donal Brennan has been appointed as chair of the Clinical Trials Advisory Council.
What is CTAC?
CTAC is the new Clinical Trials Advisory Council, created to help implement reforms that strengthen Ireland’s clinical trials ecosystem.
Why is this important for patients?
A stronger clinical trials system can improve access to innovative treatments, support better health outcomes and increase participation in high-quality research.
How does this connect to wider government policy?
The initiative aligns with Ireland’s life sciences strategy, EU biotech policy discussions and broader state priorities spanning Health, research, innovation and economic development.
Conclusion
The appointment of Professor Donal Brennan is more than a personnel update; it is a signal that Clinical Trials Ireland is moving from planning to delivery. If the new council succeeds in implementing reform, Ireland could strengthen patient access, sharpen its international research profile and create a more coordinated health innovation system for the years ahead.
Article/Image Courtesy: gov.ie
